UBS Global Biopharma Conference - KORSANA BIOSCIENCES INC
Explicit Guidance:
- Clinical Development Milestones: No financial guidance provided.
- CTA Filing: Targeted for end of calendar year (implied 2026) for Single Ascending Dose (SAD) study in Australia/New Zealand.
- IND Filing: Targeted "early next year" (implied early 2027) for Multiple Ascending Dose (MAD) study in US patients.
- Data Disclosure:
- SAD Data (Healthy Volunteers): Targeted mid-year 2027. Will assess subcutaneous (sub-Q) exposure, local tolerability, safety (including anemia), and CSF-to-serum ratio.
- MAD Interim Data: Targeted end of 2027 or Q1 2028. Will evaluate plaque clearance trajectory via PET tracers in one or two cohorts.
- Phase 3 Start: Targeted to commence global Phase 3 cognitive trials in 2028, contingent on success of Phase 1/2 expansion cohorts and safety characterization.
- Financial Metrics:
- Funding: Over $450 million in funding securing operations through 2029 (as of end of September).
- Clinical Development Milestones: No financial guidance provided.
Business-Segment Outlook:
- Product Profile (KRSA-028): Designed to be "best-in-class" by targeting pyroglutamate forms of amyloid (similar to Lilly's donanemab) combined with a TFR shuttle (similar to Roche's trontinemab).
- Dosing & Route: Aiming for monthly, low-volume subcutaneous administration via auto-injector (at-home use).
- Efficacy Goals: Targeting a plaque reduction trajectory comparable to or exceeding Roche's trontinemab (approx. 50% reduction, amyloid negativity in 3–6 months), but with lower total dose and safer profile.
- Safety Profile: Hypothesizes significantly reduced rates of Amyloid-Related Imaging Abnormalities (ARIA) compared to IV antibodies due to lower peripheral exposure and diffuse brain penetration. Specifically engineered to eliminate CDC and ADCC effector functions to prevent acute reticulocyte depletion (anemia) seen with trontinemab.
- Target Population: Initial focus on early symptomatic Alzheimer's disease; potential expansion to pre-symptomatic patients if Lilly's Trailblazer-3 data validates safety/efficacy in that cohort.
Market and Competitive Outlook:
- Competitive Landscape: Acknowledges Roche's trontinemab as the current benchmark but positions KRSA-028 as an improvement regarding convenience (sub-Q vs. IV), dosing frequency/volume, and safety (lower ARIA/anemia rates).
- Market Expansion: Anticipates the Total Addressable Market (TAM) could double if Lilly's Trailblazer-3 trial (expected H1 2027) validates treatment in pre-symptomatic populations.
- Industry Catalysts:
- Lilly Trailblazer-3: Data readout expected H1 2027.
- Roche Phase 3 Trontinemab: Data readout expected H1 2028; viewed as critical validation for the TFR shuttle mechanism.
- Competitors: Mentions AbbVie (via acquisition) and Denali (presenting at conference) as other entrants, noting TFR shuttles as a de-risked approach.
Macro / Industry Outlook:
- Treatment Paradigm: Belief that earlier intervention (pre-symptomatic) yields better cognitive benefits, though current planning focuses on the biologically proven symptomatic space.
- Regulatory: Regulatory buy-in for Phase 3 is expected via the integration of SAD and MAD data with expansion cohorts, following the precedent set by Roche.
- Pricing/Dosing Strategy: Not explicitly discussed, but the focus is on enabling a "low volume" sub-Q product to drive adoption via auto-injector.
Strategic Initiatives:
- Clinical Execution: Running an integrated Phase 1/2 study (SAD, MAD, and expansion cohorts) intended to be "Phase 3 enabling."
- Partnership: Development of KRSA-028 in partnership with Paragon Laboratories.
- Focus: Company is "well financed" with a singular focus on advancing KRSA-028; no M&A or broader pipeline expansion discussed beyond the lead program.
Risks and Headwinds to Outlook:
- Safety Risks: Potential for ARIA or anemia (reticulocyte depletion) if safety engineering does not succeed as hypothesized; FDA may be highly sensitive to ARIA in pre-symptomatic populations.
- Efficacy Risks: Inability to match the plaque clearance trajectory of trontinemab or demonstrate cognitive benefit in future trials.
- Timing Risks: Dependence on external catalysts (Lilly and Roche data readouts) to validate the pre-symptomatic market opportunity or the shuttle mechanism itself.
- Dosing Uncertainty: The exact mg dose required for monthly sub-Q administration is not yet finalized and depends on refining human bioavailability data against non-human primate models.
Management Tone on the Future:
- Confidence: High confidence in the "least risky approach" to delivering a best-in-class molecule.
- Differentiation: Management emphasizes that while Roche's data proves the mechanism, there is significant room to improve the therapeutic profile (safety/dosing).
- Strategic Focus: "We don't think it's the end of the road" regarding current therapies; expresses optimism that their engineering can overcome current liabilities (IV route, anemia, infusion reactions).
- Hedges: Uses qualifiers such as "we think," "hypothesized," and "preclinical species," acknowledging that final clinical proof is required.
Miscellaneous:
- Mechanism Specifics: The shuttle utilizes a different sequence than trontinemab but targets the same epitope with nearly identical affinity to avoid disrupting iron homeostasis.
- PK/PD Modeling: Relies on the C-average (area under the curve average) as the primary metric for efficacy and safety, drawing parallels to the donanemab IV-to-sub-Q conversion.
- CSF Metrics: Targeting a CSF-to-serum ratio of 7–8x (matching Roche data) as the primary indicator of successful shuttle functionality in the first data disclosure.
- Company
- KORSANA BIOSCIENCES INC
- Keywords
- KORSANA BIOSCIENCES INC